Following the regulatory victory of Balversa in urothelial carcinoma, Johnson & Johnson on Friday continued its bladder cancer winning streak with an 82.8% complete response rate forTAR-200 in high-risk non-muscle invasive bladder cancer.
Tag Archive for: carcinoma
The Inflation Reduction Act could put an end to blockbuster runs like that of Merck’s Keytruda. In the meantime, the drug keeps picking up more indications and positive clinical results.